Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 26
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
FASEB J ; 33(4): 5168-5180, 2019 04.
Artículo en Inglés | MEDLINE | ID: mdl-30620616

RESUMEN

The Sarcolab pilot study of 2 crewmembers, investigated before and after a 6-mo International Space Station mission, has demonstrated the substantial muscle wasting and weakness, along with disruption of muscle's oxidative metabolism. The present work aimed at evaluating the pro/anti-inflammatory status in the same 2 crewmembers (A, B). Blood circulating (c-)microRNAs (miRs), c-proteasome, c-mitochondrial DNA, and cytokines were assessed by real-time quantitative PCR or ELISA tests. Time series analysis was performed ( i.e., before flight and after landing) at 1 and 15 d of recovery (R+1 and R+15, respectively). C-biomarkers were compared with an age-matched control population and with 2-dimensional proteomic analysis of the 2 crewmembers' muscle biopsies. Striking differences were observed between the 2 crewmembers at R+1, in terms of inflamma-miRs (c-miRs-21-5p, -126-3p, and -146a-5p), muscle specific (myo)-miR-206, c-proteasome, and IL-6/leptin, thus making the 2 astronauts dissimilar to each other. Final recovery levels of c-proteasome, c-inflamma-miRs, and c-myo-miR-206 were not reverted to the baseline values in crewmember A. In both crewmembers, myo-miR-206 changed significantly after recovery. Muscle biopsy of astronaut A showed an impressive 80% increase of α-1-antitrypsin, a target of miR-126-3p. These results point to a strong stress response induced by spaceflight involving muscle tissue and the proinflammatory setting, where inflamma-miRs and myo-miR-206 mediate the systemic recovery phase after landing.-Capri, M., Morsiani, C., Santoro, A., Moriggi, M., Conte, M., Martucci, M., Bellavista, E., Fabbri, C., Giampieri, E., Albracht, K., Flück, M., Ruoss, S., Brocca, L., Canepari, M., Longa, E., Di Giulio, I., Bottinelli, R., Cerretelli, P., Salvioli, S., Gelfi, C., Franceschi, C., Narici, M., Rittweger, J. Recovery from 6-month spaceflight at the International Space Station: muscle-related stress into a proinflammatory setting.


Asunto(s)
Inflamación/metabolismo , Proteínas Musculares/metabolismo , Vuelo Espacial , Astronautas , Biomarcadores/metabolismo , Citocinas/metabolismo , ADN Mitocondrial/metabolismo , Humanos , Inflamación/inmunología , Leptina/metabolismo , MicroARNs/metabolismo , Músculo Esquelético/metabolismo , Proyectos Piloto , Complejo de la Endopetidasa Proteasomal/metabolismo , Proteómica
2.
Brain Behav Immun ; 49: 188-96, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26044087

RESUMEN

The proteasome is the core of the ubiquitin-proteasome system and is involved in synaptic protein metabolism. The incorporation of three inducible immuno-subunits into the proteasome results in the generation of the so-called immunoproteasome, which is endowed of pathophysiological functions related to immunity and inflammation. In healthy human brain, the expression of the key catalytic ß5i subunit of the immunoproteasome is almost absent, while it is induced in the epileptogenic foci surgically resected from patients with pharmaco-resistant seizures, including temporal lobe epilepsy. We show here that the ß5i immuno-subunit is induced in experimental epilepsy, and its selective pharmacological inhibition significantly prevents, or delays, 4-aminopyridine-induced seizure-like events in acute rat hippocampal/entorhinal cortex slices. These effects are stronger in slices from epileptic vs normal rats, likely due to the more prominent ß5i subunit expression in neurons and glia cells of diseased tissue. ß5i subunit is transcriptionally induced in epileptogenic tissue likely by Toll-like receptor 4 signaling activation, and independently on promoter methylation. The recent availability of selective ß5i subunit inhibitors opens up novel therapeutic opportunities for seizure inhibition in drug-resistant epilepsies.


Asunto(s)
Epilepsia/enzimología , Complejo de la Endopetidasa Proteasomal/metabolismo , Animales , Modelos Animales de Enfermedad , Corteza Entorrinal/fisiopatología , Epilepsia/fisiopatología , Hipocampo/fisiopatología , Masculino , Oligopéptidos/farmacología , Inhibidores de Proteasoma/farmacología , Subunidades de Proteína/metabolismo , ARN Mensajero/metabolismo , Ratas , Ratas Wistar
3.
Biogerontology ; 16(3): 329-40, 2015 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-25559404

RESUMEN

Sarcopenia, the progressive loss of muscle mass and strength, is a phenomenon characterizing human aging whose etiology is still not clear. While there is increasing evidence for the influence of inter-muscular adipose tissue infiltration in the development of sarcopenia, much less is known about a possible role for intra-muscular triglycerides (IMTG). IMTG accumulate in form of lipid droplets decorated by proteins such as Perilipins (Plins). In skeletal muscle the most abundant are Plin2 and Plin5. In this study we compared the expression of these two Plins in Vastus lateralis muscle samples of subjects of different age, both healthy donors (HD) and patients with limited lower limb mobility (LLMI). These latter are characterized by a condition of chronic physical inactivity. Plin2 expression resulted higher in old age for both HD and LLMI patients, while Plin5 slightly decreased only in LLMI patients. Moreover, in these patients, only Plin2 was associated with the decrease of muscle strength and the expression of factors related to muscle atrophy (MuRF1, Atrogin and p53). An increase in Plin2 and a concomitant decrease of Plin5 was also observed when we considered animal model of disuse-induced muscle atrophy. As a whole, these data indicate that Plin2 and Plin5 have a different expression pattern during muscle aging and inactivity, and only Plin2 appears to be associated with functional alterations of the muscle.


Asunto(s)
Envejecimiento/metabolismo , Regulación del Desarrollo de la Expresión Génica/fisiología , Proteínas de la Membrana/metabolismo , Músculo Esquelético/metabolismo , Atrofia Muscular/metabolismo , Proteínas/metabolismo , Sarcopenia/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Envejecimiento/genética , Animales , Biopsia , Estudios de Casos y Controles , Femenino , Regulación del Desarrollo de la Expresión Génica/genética , Humanos , Masculino , Proteínas de la Membrana/genética , Ratones Endogámicos C57BL , Ratones Mutantes , Persona de Mediana Edad , Limitación de la Movilidad , Modelos Animales , Desnervación Muscular , Proteínas Musculares/genética , Proteínas Musculares/metabolismo , Fuerza Muscular/fisiología , Músculo Esquelético/patología , Atrofia Muscular/genética , Perilipina-2 , Perilipina-5 , Coactivador 1-alfa del Receptor Activado por Proliferadores de Peroxisomas gamma , Proteínas/genética , Sarcopenia/genética , Factores de Transcripción/genética , Factores de Transcripción/metabolismo , Proteínas de Motivos Tripartitos , Proteína p53 Supresora de Tumor/genética , Proteína p53 Supresora de Tumor/metabolismo , Ubiquitina-Proteína Ligasas/genética , Ubiquitina-Proteína Ligasas/metabolismo
4.
Biochem Biophys Res Commun ; 408(1): 65-70, 2011 Apr 29.
Artículo en Inglés | MEDLINE | ID: mdl-21458417

RESUMEN

Immunoproteasome has been associated to neurodegenerative and autoimmune diseases as a marker and regulator of inflammatory mechanisms. Its expression in the brain may occur upon neuroinflammation in different cell types and affect a variety of homeostatic and inflammatory pathways including the oxidized protein clearance and the self-antigen presentation. In the present study we investigated the immunoproteasome expression in hippocampi and cortex of patients affected by different histopathological forms of pharmaco-resistent mesial temporal lobe epilepsy. We identified a pathology-specific pattern of immunoproteasome expression, which could provide insight into the complex neuroinflammatory pathogenic components of this disease.


Asunto(s)
Cisteína Endopeptidasas/metabolismo , Epilepsia del Lóbulo Temporal/inmunología , Hipocampo/inmunología , Complejo de la Endopetidasa Proteasomal/inmunología , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Complejo de la Endopetidasa Proteasomal/metabolismo , Adulto Joven
5.
Biochem Biophys Res Commun ; 397(2): 301-6, 2010 Jun 25.
Artículo en Inglés | MEDLINE | ID: mdl-20510670

RESUMEN

Despite the central role of proteasomes in relevant physiological pathways and pathological processes, this topic is unexpectedly largely unexplored in human liver. Here we present data on the presence of proteasome and immunoproteasome in human livers from normal adults, fetuses and patients affected by major hepatic diseases such as cirrhosis and chronic active hepatitis. Immunohistochemistry for constitutive (alpha4 and beta1) and inducible (LMP2 and LMP7) proteasome subunits, and for the PA28alphabeta regulator, was performed in liver samples from 38 normal subjects, 6 fetuses, 2 pediatric cases, and 19 pathological cases (10 chronic active hepatitis and 9 cirrhosis). The immunohistochemical data have been validated and quantified by Western blotting analysis. The most striking result we found was the concomitant presence in hepatocyte cytoplasm of all healthy subjects, including the pediatric cases, of constitutive proteasome and immunoproteasome subunits, as well as PA28alphabeta. At variance, immunoproteasome was not present in hepatocytes from fetuses, while a strong cytoplasmic and nuclear positivity for LMP2 and LMP7 was found in pathological samples, directly correlated to the histopathological grade of inflammation. At variance from other organs such as the brain, immunoproteasome is present in livers from normal adult and pediatric cases, in apparent absence of pathological processes, suggesting the presence of a peculiar regulation of the proteasome/immunoproteasome system, likely related to the physiological stimuli derived from the gut microbiota after birth. Other inflammatory stimuli contribute in inducing high levels of immunoproteasome in pathological conditions, where its role deserve further attention.


Asunto(s)
Feto/enzimología , Hepatitis/enzimología , Cirrosis Hepática/enzimología , Hígado/enzimología , Complejo de la Endopetidasa Proteasomal/metabolismo , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Enfermedad Crónica , Cisteína Endopeptidasas/metabolismo , Femenino , Humanos , Inmunohistoquímica , Hígado/embriología , Masculino , Persona de Mediana Edad , Complejos Multienzimáticos/metabolismo , Proteínas Musculares/metabolismo , Adulto Joven
7.
Rejuvenation Res ; 11(1): 73-82, 2008 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-17985946

RESUMEN

In this study, we investigated proteasome composition and activity in the brain of Macaca fascicularis, in order to test whether this nonhuman primate species might be a suitable animal model for anti-aging therapies in the central nervous system, addressed to the ubiquitin-proteasome system. We detected the catalytic beta subunits of constitutive proteasome, as well as the PA28 regulator and a subunit of immunoproteasome (i.e., beta1i [LMP2]), in seven adult, six old, and one young nonhuman primate brains. Subunit expression and proteasome activity were not influenced by the age of the animal in any of the brain regions (temporal and frontal cortex and cerebellum) we studied. However, an area-specific susceptibility to aged-related oxidative stress emerged. On the whole, the results suggest that, compared to humans, Macaca fascicularis primates may have a different age-dependent regulation of the ubiquitin-proteasome system and, possibly, of neuroinflammation in the brain. An in silico model of the 20S immunoproteasome containing the Macaca fascicularis alpha and beta subunits, present in database or identified by our group (i.e., LMP2), has been developed. Additional information was obtained by de novo sequencing of the beta1 (delta) subunit of Macaca fascicularis. A comparison with humans suggests that in multiprotein complexes some functional subunits, such as alpha subunits, appear to be preferentially conserved during evolution.


Asunto(s)
Envejecimiento/fisiología , Encéfalo/metabolismo , Modelos Moleculares , Complejo de la Endopetidasa Proteasomal/química , Complejo de la Endopetidasa Proteasomal/metabolismo , Envejecimiento/metabolismo , Animales , Anticuerpos/farmacología , Encéfalo/fisiología , Clonación Molecular , Cisteína Endopeptidasas/química , Cisteína Endopeptidasas/genética , Inmunoproteínas/inmunología , Inmunoproteínas/metabolismo , Inmunoproteínas/fisiología , Macaca fascicularis , Complejo de la Endopetidasa Proteasomal/inmunología , Complejo de la Endopetidasa Proteasomal/fisiología , Subunidades de Proteína/química , Subunidades de Proteína/metabolismo
8.
Nutr Rev ; 75(6): 442-455, 2017 06 01.
Artículo en Inglés | MEDLINE | ID: mdl-28595318

RESUMEN

A coherent set of epidemiological data shows that the Mediterranean diet has beneficial effects capable of preventing a variety of age-related diseases in which low-grade, chronic inflammation/inflammaging plays a major role, but the underpinning mechanism(s) is/are still unclear. It is suggested here that the Mediterranean diet can be conceptualized as a form of chronic hormetic stress, similar to what has been proposed regarding calorie restriction, the most thoroughly studied nutritional intervention. Data on the presence in key Mediterranean foods of a variety of compounds capable of exerting hormetic effects are summarized, and the mechanistic role of the nuclear factor erythroid 2 pathway is highlighted. Within this conceptual framework, particular attention has been devoted to the neurohormetic and neuroprotective properties of the Mediterranean diet, as well as to its ability to maintain an optimal balance between pro- and anti-inflammaging. Finally, the European Commission-funded project NU-AGE is discussed because it addresses a number of variables not commonly taken into consideration, such as age, sex, and ethnicity/genetics, that can modulate the hormetic effect of the Mediterranean diet.


Asunto(s)
Envejecimiento/genética , Dieta Mediterránea , Estilo de Vida Saludable , Hormesis , Inflamación/dietoterapia , Envejecimiento/fisiología , Carbohidratos de la Dieta/administración & dosificación , Fibras de la Dieta/administración & dosificación , Microbioma Gastrointestinal , Humanos , Inflamación/prevención & control , Factor 2 Relacionado con NF-E2/fisiología , Estudios Observacionales como Asunto , Fitoquímicos/administración & dosificación , Ensayos Clínicos Controlados Aleatorios como Asunto , Estrés Fisiológico , Vitaminas/administración & dosificación
9.
Sci Rep ; 7: 43718, 2017 03 09.
Artículo en Inglés | MEDLINE | ID: mdl-28276434

RESUMEN

Osteopontin is a pleiotropic cytokine that is involved in several diseases including multiple sclerosis. Secreted osteopontin is cleaved by few known proteases, modulating its pro-inflammatory activities. Here we show by in vitro experiments that secreted osteopontin can be processed by extracellular proteasomes, thereby producing fragments with novel chemotactic activity. Furthermore, osteopontin reduces the release of proteasomes in the extracellular space. The latter phenomenon seems to occur in vivo in multiple sclerosis, where it reflects the remission/relapse alternation. The extracellular proteasome-mediated inflammatory pathway may represent a general mechanism to control inflammation in inflammatory diseases.


Asunto(s)
Esclerosis Múltiple/metabolismo , Osteopontina/metabolismo , Complejo de la Endopetidasa Proteasomal/metabolismo , Secuencia de Aminoácidos , Quimiotaxis/inmunología , Células Endoteliales/metabolismo , Espacio Extracelular/metabolismo , Vesículas Extracelulares/inmunología , Vesículas Extracelulares/metabolismo , Humanos , Linfocitos/inmunología , Linfocitos/metabolismo , Modelos Moleculares , Esclerosis Múltiple/inmunología , Osteopontina/química , Osteopontina/inmunología , Complejo de la Endopetidasa Proteasomal/inmunología , Conformación Proteica , Relación Estructura-Actividad
10.
Aging Cell ; 16(2): 262-272, 2017 04.
Artículo en Inglés | MEDLINE | ID: mdl-27995756

RESUMEN

To understand why livers from aged donors are successfully used for transplants, we looked for markers of liver aging in 71 biopsies from donors aged 12-92 years before transplants and in 11 biopsies after transplants with high donor-recipient age-mismatch. We also assessed liver function in 36 age-mismatched recipients. The major findings were the following: (i) miR-31-5p, miR-141-3p, and miR-200c-3p increased with age, as assessed by microRNAs (miRs) and mRNA transcript profiling in 12 biopsies and results were validated by RT-qPCR in a total of 58 biopsies; (ii) telomere length measured by qPCR in 45 samples showed a significant age-dependent shortage; (iii) a bioinformatic approach combining transcriptome and miRs data identified putative miRs targets, the most informative being GLT1, a glutamate transporter expressed in hepatocytes. GLT1 was demonstrated by luciferase assay to be a target of miR-31-5p and miR-200c-3p, and both its mRNA (RT-qPCR) and protein (immunohistochemistry) significantly decreased with age in liver biopsies and in hepatic centrilobular zone, respectively; (iv) miR-31-5p, miR-141-3p and miR-200c-3p expression was significantly affected by recipient age (older environment) as assessed in eleven cases of donor-recipient extreme age-mismatch; (v) the analysis of recipients plasma by N-glycans profiling, capable of assessing liver functions and biological age, showed that liver function recovered after transplants, independently of age-mismatch, and recipients apparently 'rejuvenated' according to their glycomic age. In conclusion, we identified new markers of aging in human liver, their relevance in donor-recipient age-mismatches in transplantation, and offered positive evidence for the use of organs from old donors.


Asunto(s)
Envejecimiento/genética , Proteínas de Transporte de Glutamato en la Membrana Plasmática/metabolismo , Trasplante de Hígado , Hígado/metabolismo , MicroARNs/metabolismo , Donantes de Tejidos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores/sangre , Transportador 2 de Aminoácidos Excitadores , Perfilación de la Expresión Génica , Regulación del Desarrollo de la Expresión Génica , Células HEK293 , Humanos , Inmunohistoquímica , Luciferasas/metabolismo , MicroARNs/genética , Persona de Mediana Edad , ARN Mensajero/genética , ARN Mensajero/metabolismo , Reproducibilidad de los Resultados , Telómero/metabolismo , Factores de Elongación Transcripcional/genética , Factores de Elongación Transcripcional/metabolismo , Adulto Joven
11.
Neurobiol Aging ; 27(1): 54-66, 2006 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-16298241

RESUMEN

In this study, we investigated the presence and role of immunoproteasome and its LMP2 subunit polymorphism at codon 60 in Alzheimer's disease (AD). Immunoproteasome was present in brain areas such as hippocampus and cerebellum and localized in neurons, astrocytes and endothelial cells. A higher expression of immunoproteasome was found in brain of AD patients than in brain of non-demented elderly, being its expression in young brain negligible or absent. Furthermore, AD affected regions showed a partial decrease in proteasome trypsin-like activity. The study of LMP2 polymorphism (R/H) showed that it does not influence LMP2 expression (neither the mRNA nor mature protein) in brain tissue. However, control brain areas of AD patients carrying the RR genotype showed an increased proteasome activity in comparison with RH carriers. To test whether this effect of the genotype might be related to AD onset we performed a genetic study, which allowed us to exclude an association of LMP2 codon 60 polymorphism with AD onset, despite its influence on the proteasome activity in human brain.


Asunto(s)
Envejecimiento/genética , Envejecimiento/metabolismo , Enfermedad de Alzheimer/genética , Encéfalo/metabolismo , Cisteína Endopeptidasas/genética , Cisteína Endopeptidasas/metabolismo , Complejo de la Endopetidasa Proteasomal/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Cadáver , Femenino , Predisposición Genética a la Enfermedad/genética , Humanos , Técnicas In Vitro , Masculino , Persona de Mediana Edad , Prevalencia , Complejo de la Endopetidasa Proteasomal/genética , Medición de Riesgo/métodos , Factores de Riesgo
12.
Elife ; 4: e07545, 2015 Sep 22.
Artículo en Inglés | MEDLINE | ID: mdl-26393687

RESUMEN

Proteasomal protein degradation is a key determinant of protein half-life and hence of cellular processes ranging from basic metabolism to a host of immunological processes. Despite its importance the mechanisms regulating proteasome activity are only incompletely understood. Here we use an iterative and tightly integrated experimental and modelling approach to develop, explore and validate mechanistic models of proteasomal peptide-hydrolysis dynamics. The 20S proteasome is a dynamic enzyme and its activity varies over time because of interactions between substrates and products and the proteolytic and regulatory sites; the locations of these sites and the interactions between them are predicted by the model, and experimentally supported. The analysis suggests that the rate-limiting step of hydrolysis is the transport of the substrates into the proteasome. The transport efficiency varies between human standard- and immuno-proteasomes thereby impinging upon total degradation rate and substrate cleavage-site usage.


Asunto(s)
Regulación de la Expresión Génica , Complejo de la Endopetidasa Proteasomal/metabolismo , Animales , Línea Celular , Humanos , Cinética , Hígado/enzimología , Ratones , Modelos Biológicos , Transporte de Proteínas , Proteolisis
13.
Nutrients ; 7(4): 2589-621, 2015 Apr 09.
Artículo en Inglés | MEDLINE | ID: mdl-25859884

RESUMEN

Aging is considered the major risk factor for cancer, one of the most important mortality causes in the western world. Inflammaging, a state of chronic, low-level systemic inflammation, is a pervasive feature of human aging. Chronic inflammation increases cancer risk and affects all cancer stages, triggering the initial genetic mutation or epigenetic mechanism, promoting cancer initiation, progression and metastatic diffusion. Thus, inflammaging is a strong candidate to connect age and cancer. A corollary of this hypothesis is that interventions aiming to decrease inflammaging should protect against cancer, as well as most/all age-related diseases. Epidemiological data are concordant in suggesting that the Mediterranean Diet (MD) decreases the risk of a variety of cancers but the underpinning mechanism(s) is (are) still unclear. Here we review data indicating that the MD (as a whole diet or single bioactive nutrients typical of the MD) modulates multiple interconnected processes involved in carcinogenesis and inflammatory response such as free radical production, NF-κB activation and expression of inflammatory mediators, and the eicosanoids pathway. Particular attention is devoted to the capability of MD to affect the balance between pro- and anti-inflammaging as well as to emerging topics such as maintenance of gut microbiota (GM) homeostasis and epigenetic modulation of oncogenesis through specific microRNAs.


Asunto(s)
Envejecimiento , Dieta Mediterránea , Inflamación/prevención & control , Neoplasias/prevención & control , Enfermedad Crónica , Microbioma Gastrointestinal , Tracto Gastrointestinal/microbiología , Humanos
14.
Ageing Res Rev ; 2(4): 419-32, 2003 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-14522244

RESUMEN

Aging is a complex process which is accompanied with the decline and the reshaping of different functions of the body. In particular the immune system is characterized, during ageing (immunosenescence) by a remodeling of innate immunity (well preserved, up-regulated) and clonotypical immunity (severely altered) and by the occurrence of a chronic inflammatory process (inflammaging) which are, at least in part, genetically controlled. In this scenario, it can be anticipated that a crucial role is played by age-related structural and functional alterations and modifications of proteasomes and immunoproteasomes, the last being a key component of antigen processing and MHC class I antigen presentation. A variety of experimental data are available, suggesting that proteasomes are affected by age, and that in centenarians they are relatively preserved. On the contrary, few data are available on immunoproteasomes, likely as a consequence of the poverty of suitable cellular models. Lymphoblastoid cell lines from EBV immortalized B cells from old donors is envisaged as a possible model for the study of immunoproteasomes in humans and their changes with age. Thus, basic questions such as those related to possible consequences, for immune responses in infectious diseases and cancer, of age-related alterations of antigen processing and presenting, change with age of self-antigen repertoire, and the genetic basis of immunoproteasome activity and its change with age, remain largely unanswered.


Asunto(s)
Envejecimiento/inmunología , Cisteína Endopeptidasas/inmunología , Cisteína Endopeptidasas/fisiología , Complejos Multienzimáticos/inmunología , Complejos Multienzimáticos/fisiología , Anciano , Envejecimiento/fisiología , Animales , Humanos , Inflamación/inmunología , Inflamación/patología , Longevidad/fisiología , Complejo de la Endopetidasa Proteasomal
15.
Autoimmune Dis ; 2014: 739705, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24523959

RESUMEN

The ubiquitin-proteasome system is the major intracellular molecular machinery for protein degradation and maintenance of protein homeostasis in most human cells. As ubiquitin-proteasome system plays a critical role in the regulation of the immune system, it might also influence the development and progression of multiple sclerosis (MS). Both ex vivo analyses and animal models suggest that activity and composition of ubiquitin-proteasome system are altered in MS. Proteasome isoforms endowed of immunosubunits may affect the functionality of different cell types such as CD8(+) and CD4(+) T cells and B cells as well as neurons during MS development. Furthermore, the study of proteasome-related biomarkers, such as proteasome antibodies and circulating proteasomes, may represent a field of interest in MS. Proteasome inhibitors are already used as treatment for cancer and the recent development of inhibitors selective for immunoproteasome subunits may soon represent novel therapeutic approaches to the different forms of MS. In this review we describe the current knowledge on the potential role of proteasomes in MS and discuss the pro et contra of possible therapies for MS targeting proteasome isoforms.

16.
Mech Ageing Dev ; 141-142: 26-34, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25265087

RESUMEN

Owing to organ shortage, livers from old donors are increasingly used for transplantation. The function and duration of such transplanted livers are apparently comparable to those from young donors, suggesting that, despite some morphological and structural age-related changes, no major functional changes do occur in liver with age. We tested this hypothesis by performing a comprehensive study on proteasomes, major cell organelles responsible for proteostasis, in liver biopsies from heart-beating donors. Oxidized and poly-ubiquitin conjugated proteins did not accumulate with age and the three major proteasome proteolytic activities were similar in livers from young and old donors. Analysis of proteasomes composition showed an age-related increased of ß5i/α4 ratio, suggesting a shift toward proteasomes containing inducible subunits and a decreased content of PA28α subunit, mainly in the cytosol of hepatocytes. Thus our data suggest that, proteasomes activity is well preserved in livers from aged donors, concomitantly with subtle changes in proteasome subunit composition which might reflect the occurrence of a functional remodelling to maintain an efficient proteostasis. Gender differences are emerging and they deserve further investigations owing to the different aging trajectories between men and women. Finally, our data support the safe use of livers from old donors for transplantation.


Asunto(s)
Envejecimiento/metabolismo , Hígado/enzimología , Complejo de la Endopetidasa Proteasomal/metabolismo , Proteolisis , Caracteres Sexuales , Adolescente , Adulto , Femenino , Humanos , Hígado/citología , Masculino , Persona de Mediana Edad
17.
Curr Pharm Des ; 19(4): 702-18, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23016859

RESUMEN

Immunoproteasome is an emerging biological target that constitutes a key element not only in antigen presentation but also in T cell and cytokine regulation as well as cellular homeostasis. Respect to standard proteasome, the inducible expression and different sensitivity towards activity modulators of immunoproteasome render it a potential therapeutic target for tumours and central nervous system diseases. In this review we report the cutting edge studies for understanding when immunoproteasome expression is induced and how it regulates pivotal pathways involved in tumours and neuropathologies, including apoptosis and inflammation. We emphasize its role as a new pharmacological target by describing the recent medicinal chemistry efforts aimed at design selective small-molecule modulators of both standard- and immuno-proteasome forms. Finally, we also present an in silico model of the human immunoproteasome structure by the major molecular differences with the 20S standard proteasome and discuss the perspective for the design of novel specific smallmolecule modulators for the different proteasome isoforms.


Asunto(s)
Enfermedades del Sistema Nervioso Central/tratamiento farmacológico , Neoplasias/tratamiento farmacológico , Complejo de la Endopetidasa Proteasomal/inmunología , Animales , Presentación de Antígeno/inmunología , Apoptosis/inmunología , Enfermedades del Sistema Nervioso Central/inmunología , Simulación por Computador , Citocinas/inmunología , Diseño de Fármacos , Humanos , Terapia Molecular Dirigida , Neoplasias/inmunología , Isoformas de Proteínas , Linfocitos T/inmunología
18.
PLoS One ; 8(8): e73709, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23977392

RESUMEN

Human aging is associated with a progressive loss of muscle mass and strength and a concomitant fat accumulation in form of inter-muscular adipose tissue, causing skeletal muscle function decline and immobilization. Fat accumulation can also occur as intra-muscular triglycerides (IMTG) deposition in lipid droplets, which are associated with perilipin proteins, such as Perilipin2 (Plin2). It is not known whether Plin2 expression changes with age and if this has consequences on muscle mass and strength. We studied the expression of Plin2 in the vastus lateralis (VL) muscle of both healthy subjects and patients affected by lower limb mobility limitation of different age. We found that Plin2 expression increases with age, this phenomenon being particularly evident in patients. Moreover, Plin2 expression is inversely correlated with quadriceps strength and VL thickness. To investigate the molecular mechanisms underpinning this phenomenon, we focused on IGF-1/p53 network/signalling pathway, involved in muscle physiology. We found that Plin2 expression strongly correlates with increased p53 activation and reduced IGF-1 expression. To confirm these observations made on humans, we studied mice overexpressing muscle-specific IGF-1, which are protected from sarcopenia. These mice resulted almost negative for the expression of Plin2 and p53 at two years of age. We conclude that fat deposition within skeletal muscle in form of Plin2-coated lipid droplets increases with age and is associated with decreased muscle strength and thickness, likely through an IGF-1- and p53-dependent mechanism. The data also suggest that excessive intramuscular fat accumulation could be the initial trigger for p53 activation and consequent loss of muscle mass and strength.


Asunto(s)
Proteínas de la Membrana/metabolismo , Debilidad Muscular/metabolismo , Debilidad Muscular/patología , Músculo Esquelético/metabolismo , Músculo Esquelético/patología , Sarcopenia/metabolismo , Sarcopenia/patología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Envejecimiento/metabolismo , Envejecimiento/patología , Animales , Humanos , Factor I del Crecimiento Similar a la Insulina/metabolismo , Ratones , Fuerza Muscular , Debilidad Muscular/complicaciones , Debilidad Muscular/fisiopatología , Músculo Esquelético/fisiopatología , Perilipina-2 , Sarcopenia/complicaciones , Sarcopenia/fisiopatología , Transducción de Señal , Proteína p53 Supresora de Tumor/metabolismo , Adulto Joven
19.
Curr Pharm Des ; 19(9): 1675-9, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23589904

RESUMEN

Inflamm-aging, that is the age-associated inflammatory status, is considered one of the most striking consequences of immunosenescence, as it is believed to be linked to the majority of age-associated diseases sharing an inflammatory basis. Nevertheless, evidence is emerging that inflamm-aging is at least in part independent from immunological stimuli. Moreover, centenarians who avoided or delayed major inflammatory diseases display markers of inflammation. In this paper we proposed a reappraisal of the concept of inflamm-aging, suggesting that its pathological effects can be independent from the total amount of pro-inflammatory mediators, but they would be rather associated with the anatomical district and type of cells where they are produced and where they primarily act.


Asunto(s)
Envejecimiento , Senescencia Celular , Sistema Inmunológico/fisiología , Inflamación/fisiopatología , Longevidad , Apoptosis , ADN/sangre , Humanos
20.
PLoS One ; 7(3): e32678, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22403694

RESUMEN

Inflammation is part of a complex physiological response to harmful stimuli and pathogenic stress. The five components of the Nuclear Factor κB (NF-κB) family are prominent mediators of inflammation, acting as key transcriptional regulators of hundreds of genes. Several signaling pathways activated by diverse stimuli converge on NF-κB activation, resulting in a regulatory system characterized by high complexity. It is increasingly recognized that the number of components that impinges upon phenotypic outcomes of signal transduction pathways may be higher than those taken into consideration from canonical pathway representations. Scope of the present analysis is to provide a wider, systemic picture of the NF-κB signaling system. Data from different sources such as literature, functional enrichment web resources, protein-protein interaction and pathway databases have been gathered, curated, integrated and analyzed in order to reconstruct a single, comprehensive picture of the proteins that interact with, and participate to the NF-κB activation system. Such a reconstruction shows that the NF-κB interactome is substantially different in quantity and quality of components with respect to canonical representations. The analysis highlights that several neglected but topologically central proteins may play a role in the activation of NF-κB mediated responses. Moreover the interactome structure fits with the characteristics of a bow tie architecture. This interactome is intended as an open network resource available for further development, refinement and analysis.


Asunto(s)
FN-kappa B/metabolismo , Mapeo de Interacción de Proteínas/métodos , Transducción de Señal , Humanos , Anotación de Secuencia Molecular
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA